MNPR · NASDAQ · Biotechnology

Monopar Therapeutics (MNPR)

Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.

$96.63
After hours+0.15 (+0.16%)
At close$96.48(+0.79%)
  1. Monopar Appoints Jeffrey D. Kent, M.D.

    GlobeNewsWireLeadership